Xiangming Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiangming Ji has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Andreea Geamanu
Department of Nutrition and Food Science, Wayne State University, Detroit, MI
2 shared publicationsCorene Canning
Department of Nutrition and Food Science, Wayne State University, Detroit, MI 48202, USA
2 shared publicationsFazlul H Sarkar
Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, MI
2 shared publicationsKequan Zhou
2 shared publicationsShi Sun
2 shared publicationsSmiti Gupta
2 shared publications
Latest Publications
- 1 May 2013
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 147 (1) , 259-262
Antibacterial and cytotoxic activity of isoprenylated coumarin mammea A/AA isolated from Mammea africana
- 1 May 2013
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 147 (1) , 259-262
Antibacterial and cytotoxic activity of isoprenylated coumarin mammea A/AA isolated from Mammea africana
- 15 August 2012
- Published by Taylor & Francis
- p. 151-162
Potential of Tocotrienols in Lung Cancer
- Open Access
- 21 March 2012
- Published by Wiley in International Journal of Cancer
- Vol. 131 (11) , 2668-2677
Delta‐tocotrienol suppresses Notch‐1 pathway by upregulating miR‐34a in nonsmall cell lung cancer cells
MicroRNAs (miRNAs) are small noncoding RNAs that play critical roles in regulating various cellular functions by transcriptional silencing. miRNAs can function as either oncogenes or tumor suppressors (oncomirs), depending on cancer types. In our study, using miRNA microarray, we observed that downregulation of the Notch‐1 pathway, by delta‐tocotrienol, correlated with upregulation of miR‐34a, in nonsmall cell lung cancer cells (NSCLC). Moreover, re‐expression of miR‐34a by transfection in NSCLC cells resulted in inhibition of cell growth and invasiveness, induction of apoptosis and enhanced p53 activity. Furthermore, cellular mechanism studies revealed that induction of miR‐34a decreased the expression of Notch‐1 and its downstream targets including Hes‐1, Cyclin D1, Survivin and Bcl‐2. Our findings suggest that delta‐tocotrienol is a nontoxic activator of mir‐34a which can inhibit NSCLC cell proliferation, induce apoptosis and inhibit invasion, and thus offering a potential starting point for the design of novel anticancer agents.
- 21 March 2012
- Published by Wiley in International Journal of Cancer
- Vol. 131 (11) , 2668-2677
Open AccessDelta‐tocotrienol suppresses Notch‐1 pathway by upregulating miR‐34a in nonsmall cell lung cancer cells
MicroRNAs (miRNAs) are small noncoding RNAs that play critical roles in regulating various cellular functions by transcriptional silencing. miRNAs can function as either oncogenes or tumor suppressors (oncomirs), depending on cancer types. In our study, using miRNA microarray, we observed that downregulation of the Notch‐1 pathway, by delta‐tocotrienol, correlated with upregulation of miR‐34a, in nonsmall cell lung cancer cells (NSCLC). Moreover, re‐expression of miR‐34a by transfection in NSCLC cells resulted in inhibition of cell growth and invasiveness, induction of apoptosis and enhanced p53 activity. Furthermore, cellular mechanism studies revealed that induction of miR‐34a decreased the expression of Notch‐1 and its downstream targets including Hes‐1, Cyclin D1, Survivin and Bcl‐2. Our findings suggest that delta‐tocotrienol is a nontoxic activator of mir‐34a which can inhibit NSCLC cell proliferation, induce apoptosis and inhibit invasion, and thus offering a potential starting point for the design of novel anticancer agents.
- 19 May 2011
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (10) , 2773-2783
Inhibition of cell growth and induction of apoptosis in non-small cell lung cancer cells by delta-tocotrienol is associated with notch-1 down-regulation
Lung cancer is the leading cause of death among all cancers. Non‐small cell lung cancer accounts for 80% of lung cancer with a 5‐year survival rate of 16%. Notch pathway, especially Notch‐1 is up‐regulated in a subgroup of non‐small cell lung cancer patients. Since Notch‐1 signaling plays an important role in cell proliferation, differentiation, and apoptosis, down‐regulation of Notch‐1 may exert anti‐tumor effects. The objective of this study was to investigate whether delta‐tocotrienol, a naturally occurring isoform of Vitamin E, inhibits non‐small cell lung cancer cell growth via Notch signaling. Treatment with delta‐tocotrienol resulted in a dose and time dependent inhibition of cell growth, cell migration, tumor cell invasiveness, and induction of apoptosis. Real‐time RT‐PCR and western blot analysis showed that antitumor activity by delta‐tocotrienol was associated with a decrease in Notch‐1, Hes‐1, Survivin, MMP‐9, VEGF, and Bcl‐XL expression. In addition, there was a decrease in NF‐κB‐DNA binding activity. These results suggest that down‐regulation of Notch‐1, via inhibition of NF‐κB signaling pathways by delta‐tocotrienol, could provide a potential novel approach for prevention of tumor progression in non‐small cell lung cancer. J. Cell. Biochem. 112: 2773–2783, 2011.
- 19 May 2011
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (10) , 2773-2783
Inhibition of cell growth and induction of apoptosis in non-small cell lung cancer cells by delta-tocotrienol is associated with notch-1 down-regulation
Lung cancer is the leading cause of death among all cancers. Non‐small cell lung cancer accounts for 80% of lung cancer with a 5‐year survival rate of 16%. Notch pathway, especially Notch‐1 is up‐regulated in a subgroup of non‐small cell lung cancer patients. Since Notch‐1 signaling plays an important role in cell proliferation, differentiation, and apoptosis, down‐regulation of Notch‐1 may exert anti‐tumor effects. The objective of this study was to investigate whether delta‐tocotrienol, a naturally occurring isoform of Vitamin E, inhibits non‐small cell lung cancer cell growth via Notch signaling. Treatment with delta‐tocotrienol resulted in a dose and time dependent inhibition of cell growth, cell migration, tumor cell invasiveness, and induction of apoptosis. Real‐time RT‐PCR and western blot analysis showed that antitumor activity by delta‐tocotrienol was associated with a decrease in Notch‐1, Hes‐1, Survivin, MMP‐9, VEGF, and Bcl‐XL expression. In addition, there was a decrease in NF‐κB‐DNA binding activity. These results suggest that down‐regulation of Notch‐1, via inhibition of NF‐κB signaling pathways by delta‐tocotrienol, could provide a potential novel approach for prevention of tumor progression in non‐small cell lung cancer. J. Cell. Biochem. 112: 2773–2783, 2011.
- 22 March 2010
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 58 (7) , 4508-4512
Comparison of Different Strategies for Soybean Antioxidant Extraction
Three extraction strategies including Soxhlet extraction, conventional solid−liquid extraction, and ultrasonic-assisted extraction (UAE) were compared for their efficiency to extract phenolic antioxidants from Virginia-grown soybean seeds. Five extraction solvents were evaluated in UAE and the conventional extraction. The soybean extracts were compared for their total phenolic contents (TPC), oxygen radical absorbance capacity (ORAC), and 2,2-diphenyl-1-picrylhydrazyl radical (DPPH•) scavenging activities. The results showed that UAE improved the extraction of soybean phenolic compounds by >54% compared to the conventional and Soxhlet extractions. Among the tested solvents, 50% acetone was the most efficient for extracting soybean phenolic compounds. There was no significant correlation between the TPC and antioxidant activities of the soybean extracts. The extracts prepared by 70% ethanol had the highest ORAC values. Overall, UAE with 50% acetone or 70% ethanol is recommended for extracting soybean antioxidants on the basis of the TPC and ORAC results.
- 22 March 2010
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 58 (7) , 4508-4512
Comparison of Different Strategies for Soybean Antioxidant Extraction
Three extraction strategies including Soxhlet extraction, conventional solid−liquid extraction, and ultrasonic-assisted extraction (UAE) were compared for their efficiency to extract phenolic antioxidants from Virginia-grown soybean seeds. Five extraction solvents were evaluated in UAE and the conventional extraction. The soybean extracts were compared for their total phenolic contents (TPC), oxygen radical absorbance capacity (ORAC), and 2,2-diphenyl-1-picrylhydrazyl radical (DPPH•) scavenging activities. The results showed that UAE improved the extraction of soybean phenolic compounds by >54% compared to the conventional and Soxhlet extractions. Among the tested solvents, 50% acetone was the most efficient for extracting soybean phenolic compounds. There was no significant correlation between the TPC and antioxidant activities of the soybean extracts. The extracts prepared by 70% ethanol had the highest ORAC values. Overall, UAE with 50% acetone or 70% ethanol is recommended for extracting soybean antioxidants on the basis of the TPC and ORAC results.
- Open Access
- 8 January 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 1-9
Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
Background: The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. An integrated analysis of both genes could help define the proportion of patients that would potentially benefit from targeted therapies. Methods: We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH). Results: The EGFR was expressed in 59% of the cases, with a 2+/3+ staining intensity in 38%. HER2-neu expression was found in 35%, with a 2/3+ staining in 18%. No mutations were found in exons 18–24 of the TK domains of EGFR and HER2-neu. High polysomy of the EGFR gene was observed in 13% of the invasive epthelial cancers and amplification of the HER2-neu gene was found in 10% and correlated with a high expression level by immunohistochemistry. Mutations within the tyrosine kinase domain were not found in the entire TK domain of both genes, but have been found in very rare cases by others. Conclusion: Genomic alteration of the HER2-neu and EGFR genes is frequent (25%) in ovarian cancer. EGFR/HER2-neu targeted therapies should be investigated prospectively and specifically in that subset of patients.
- 8 January 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 1-9
Open AccessGenomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
Background: The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. An integrated analysis of both genes could help define the proportion of patients that would potentially benefit from targeted therapies. Methods: We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH). Results: The EGFR was expressed in 59% of the cases, with a 2+/3+ staining intensity in 38%. HER2-neu expression was found in 35%, with a 2/3+ staining in 18%. No mutations were found in exons 18–24 of the TK domains of EGFR and HER2-neu. High polysomy of the EGFR gene was observed in 13% of the invasive epthelial cancers and amplification of the HER2-neu gene was found in 10% and correlated with a high expression level by immunohistochemistry. Mutations within the tyrosine kinase domain were not found in the entire TK domain of both genes, but have been found in very rare cases by others. Conclusion: Genomic alteration of the HER2-neu and EGFR genes is frequent (25%) in ovarian cancer. EGFR/HER2-neu targeted therapies should be investigated prospectively and specifically in that subset of patients.